India’s Patent Revocations: Strengthening Access and Challenging Evergreening

The Indian Patent Office’s recent decision to revoke Novartis’ patent on the cardiac drug Vymada marks another chapter in the country’s robust stand for patient access against the tide of patent evergreening. At the heart of this and previous landmark cases lies Section 3(d) of the Indian Patent Act—a provision designed to ensure genuine innovation…